对来自五大洲的革兰阳性临床病原体进行的替拉万星活性的全球评估和更新（2010 年）。
Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
机构信息
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2012 Jul;56(7):3999-4004. doi: 10.1128/AAC.00011-12. Epub 2012 Apr 16.
Abstract
A total of 15,480 Gram-positive pathogens were collected from 89 sites in the United States, Europe, the Asia-Pacific region, and Latin America in 2010. Telavancin was active against indicated Staphylococcus aureus (MIC(50/90), 0.12/0.25 μg/ml), vancomycin-susceptible Enterococcus faecalis (MIC(50/90), 0.5/0.5 μg/ml), and beta-hemolytic (MIC(50/90), 0.06/0.12 μg/ml) and viridans group streptococcus (MIC(50/90), 0.03/0.06 μg/ml) isolates. These MIC results showed potency for telavancin equal to or greater than that of comparators. These in vitro data confirm a continued potent activity of telavancin when tested against contemporary Gram-positive clinical isolates.
摘要
2010 年，从美国、欧洲、亚太地区和拉丁美洲的 89 个地点共采集了 15480 株革兰氏阳性病原体。替拉万星对指示性金黄色葡萄球菌（MIC（50/90），0.12/0.25μg/ml）、万古霉素敏感粪肠球菌（MIC（50/90），0.5/0.5μg/ml）和β溶血性（MIC（50/90），0.06/0.12μg/ml）和草绿色链球菌（MIC（50/90），0.03/0.06μg/ml）分离株具有活性。这些 MIC 结果表明，替拉万星的效力与对照药物相当或更强。这些体外数据证实了替拉万星在测试针对当代革兰氏阳性临床分离株时仍然具有强大的活性。
相似文献
1
Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
Antimicrob Agents Chemother. 2012 Jul;56(7):3999-4004. doi: 10.1128/AAC.00011-12. Epub 2012 Apr 16.
2
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
J Chemother. 2010 Oct;22(5):304-11. doi: 10.1179/joc.2010.22.5.304.
3
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.
4
Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
Diagn Microbiol Infect Dis. 2015 Apr;81(4):275-9. doi: 10.1016/j.diagmicrobio.2014.12.011. Epub 2014 Dec 31.
5
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
J Glob Antimicrob Resist. 2017 Sep;10:271-276. doi: 10.1016/j.jgar.2017.03.018. Epub 2017 Jul 19.
6
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
Diagn Microbiol Infect Dis. 2010 Aug;67(4):359-68. doi: 10.1016/j.diagmicrobio.2010.03.009.
7
Antimicrobial Activity of Telavancin Tested Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017).
Microb Drug Resist. 2020 Aug;26(8):934-943. doi: 10.1089/mdr.2019.0104. Epub 2020 Feb 12.
8
Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
Diagn Microbiol Infect Dis. 2012 Jan;72(1):113-7. doi: 10.1016/j.diagmicrobio.2011.09.023. Epub 2011 Nov 10.
9
In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.
Microb Drug Resist. 2017 Sep;23(6):718-726. doi: 10.1089/mdr.2017.0022. Epub 2017 Jul 20.
10
Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01715-19.
引用本文的文献
1
Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00516-19. Print 2019 Aug.
2
Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.
Infect Dis Ther. 2016 Dec;5(4):535-544. doi: 10.1007/s40121-016-0133-y. Epub 2016 Oct 7.
3
Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
Ther Adv Respir Dis. 2016 Aug;10(4):368-78. doi: 10.1177/1753465816651594. Epub 2016 Jun 23.
4
Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.
Adv Ther. 2016 Feb;33(2):151-66. doi: 10.1007/s12325-016-0293-x. Epub 2016 Feb 9.
5
Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Antimicrob Agents Chemother. 2015 Sep;59(9):5529-34. doi: 10.1128/AAC.00773-15. Epub 2015 Jun 29.
6
Update on the emerging role of telavancin in hospital-acquired infections.
Ther Clin Risk Manag. 2015 Apr 13;11:605-10. doi: 10.2147/TCRM.S57376. eCollection 2015.
7
Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
Antimicrob Agents Chemother. 2015 Mar;59(3):1811-4. doi: 10.1128/AAC.04616-14. Epub 2015 Jan 5.
8
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Clin Infect Dis. 2015 Mar 1;60(5):787-96. doi: 10.1093/cid/ciu971. Epub 2014 Dec 3.
9
Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.
J Clin Microbiol. 2014 Sep;52(9):3399-401. doi: 10.1128/JCM.01210-14. Epub 2014 Jun 11.
10
Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.
Expert Rev Clin Pharmacol. 2014 May;7(3):327-40. doi: 10.1586/17512433.2014.909281. Epub 2014 Apr 9.
本文引用的文献
1
Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).
Diagn Microbiol Infect Dis. 2011 Sep;71(1):93-7. doi: 10.1016/j.diagmicrobio.2011.05.012.
2
Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv17-iv21. doi: 10.1093/jac/dkr073.
3
In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-7. doi: 10.1016/j.diagmicrobio.2010.10.031.
4
In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.
Diagn Microbiol Infect Dis. 2011 Mar;69(3):275-9. doi: 10.1016/j.diagmicrobio.2010.09.017.
5
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
Diagn Microbiol Infect Dis. 2010 Aug;67(4):359-68. doi: 10.1016/j.diagmicrobio.2010.03.009.
6
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Antimicrob Agents Chemother. 2010 Jun;54(6):2704-6. doi: 10.1128/AAC.00301-10. Epub 2010 Apr 12.
7
Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24. doi: 10.1128/AAC.00742-09. Epub 2009 Jul 20.
8
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83. doi: 10.1128/AAC.01710-08. Epub 2009 May 26.
9
In vitro activity of telavancin against resistant gram-positive bacteria.
Antimicrob Agents Chemother. 2008 Jul;52(7):2647-52. doi: 10.1128/AAC.01398-07. Epub 2008 Apr 28.
10
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.
Zotero 插件